NEXI (NexImmune) Total Liabilities: $4.94 Mil (As of Jun. 2024)


What is NexImmune Total Liabilities?

NexImmune NEXI Total Liabilities is $4.94 Mil as of Jun. 2024.

NexImmune's Total Liabilities for the quarter that ended in Jun. 2024 was $4.94 Mil.

NexImmune's quarterly Total Liabilities increased from Dec. 2023 ($5.08 Mil) to Mar. 2024 ($6.02 Mil) but then declined from Mar. 2024 ($6.02 Mil) to Jun. 2024 ($4.94 Mil).

NexImmune's annual Total Liabilities increased from Dec. 2021 ($7.27 Mil) to Dec. 2022 ($10.76 Mil) but then declined from Dec. 2022 ($10.76 Mil) to Dec. 2023 ($5.08 Mil).

NexImmune Total Liabilities Historical Data

* Premium members only.

The historical data trend for NexImmune's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune Total Liabilities Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 3.11 27.06 7.27 10.76 5.08

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.47 6.31 5.08 6.02 4.94

NexImmune Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NexImmune's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.084+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.08

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=8.594-3.51
=5.08

NexImmune's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.737+(0+0.204
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.94

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=5.861-0.921
=4.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $4.94 Mil mean?
NexImmune (NEXI) has a Total Liabilities of $4.94 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NexImmune and its competitors.
Is NexImmune's Total Liabilities too high?
NexImmune's current Total Liabilities is $4.94 Mil.
How does NexImmune's Total Liabilities compare to PPCBD and ENDV?
NexImmune's Total Liabilities of $4.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NexImmune and its competitors. NexImmune's current Total Liabilities is $4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (NEXI) has a current Total Liabilities of $4.94 Mil. The current Total Liabilities is $4.94 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NexImmune (NEXI), the current Total Liabilities is $4.94 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.